Pfizer, Lilly, Sanofi, Amgen And Others Named In Indian Clinical Trial Death Compensation Inquiry
This article was originally published in The Pink Sheet Daily
Executive Summary
The news of the health ministry probe earlier this month stirred debate about the gaping holes in Indian clinical trial laws and the country's loose enforcement framework, particularly as clinical trial projects flow rapidly into the country.